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Introduction
============

Around 10%-20% of patients undergoing lower extremity re-vascularization experience a surgical site infection (SSI) \[[@REF1]\]. In the United States, SSIs increase healthcare spending by approximately \$1.6 billion per year \[[@REF2]\]. Many factors contribute to the high infection rates of extremity bypass procedures. Proximity of femoral incisions to genitalia and inguinal lymphatics can make these incisions problematic \[[@REF1]\]. This area can be extremely difficult to keep clean and dry.

The use of closed incisional negative pressure therapy (ciNPT) has been shown to decrease SSIs for inguinal incisions \[[@REF3]-[@REF5]\]. It has also been shown to be cost effective in high-risk patients \[[@REF6],[@REF7]\]. We sought to identify if the routine use of ciNPT is cost effective for use in all extremity bypass patients. The routine use of ciNPT was undertaken in extremity bypass patients at our institution. We performed a retrospective chart review on patients both before and after the institution of routine ciNPT.

Materials and methods
=====================

We conducted a retrospective chart review on patients who had a surgical bypass procedure before and after the routine use of ciNPT (Table [1](#TAB1){ref-type="table"}). Institutional Review Board approval was obtained to conduct our retrospective chart review. This time frame was chosen as our institution has now transitioned to the routine use of ciNPT on all bypass patients. Our institution transitioned to the routine use of ciNPT because of a prior surge in bypass infection rates. All procedures were performed at a single institution in a group of eight vascular surgeons. A four-month overlap period (May 2018 to August 2018) was allowed for physicians to become comfortable with the device and familiarize nurses with the product. This overlap period was not included in the study. All ciNPT procedures were performed utilizing Prevena™ (3M + KCI, St. Paul, MN). All patients were instructed by a clinical nurse upon discharge to maintain the dressing for a duration of seven days. All devices were placed utilizing standard settings. The Prevena device does not allow adjustment of pressure. Proximal groin incisions received ciNPT and distal incisions received a standard dressing. Inclusion criteria included having a re-vascularization procedure performed during Group A and B periods. One patient in each group was excluded from the study due to patient expiration before 90 days. Both cases were unrelated to infection and incisions were healing as expected per chart review.

###### Group divisions

  ----------------------------------------------------------------------- -----------------------------------------------------------
  Group A                                                                 Group B
  September 2017-April 2018                                               September 2018-April 2019
  Before the introduction of negative pressure wound incisional therapy   Routine use of negative pressure wound incisional therapy
  102 patients                                                            113 patients
  ----------------------------------------------------------------------- -----------------------------------------------------------

Demographic variables were compared between Group A and Group B. Demographic variables studied include gender, presence of diabetes, current smoking status, hyperlipidemia, use of prosthetic graft, femoral incision and presence of redo operative field. Primary outcomes included deep and overall infection rates. Secondary outcomes included cost savings. We hypothesized that after the routine use of ciNPT, our deep and overall infection rates would decrease and thus result in cost savings. Testing was done with chi-square or Fisher\'s exact test depending on cell count to determine if there was an association between the groups and the variables tested. Continuous variables were tested using a Kruskal-Wallis test. Statistical significance was set at a level of 0.05. Categorical variables are displayed as counts and percentages while continuous data is displayed as mean with the inter-quartile range (IQR). Determination of infection was based on National Healthcare Safety Network (NHSN) classification guidelines. Superficial infections did not violate fascia. Deep infections had sub-fascial involvement. Graft infections included the bypass graft. Patients underwent surveillance for 90 days to determine if they had a superficial or deep infection. Patients with re-vascularization procedures were seen in the vascular office within one month of hospital discharge. Pictures of the wounds were taken if there were any concerning features. If patients were not seen in the office, they were called by a clinical nurse and again at 90 days. Patients were followed up for one year to determine if they had a graft infection. This follow-up was performed by the vascular quality department utilizing phone calls and scheduling a visit if a problem was present. Cost analysis was performed utilizing internal cost metrics at our institution.

Results
=======

There was no difference between Group A or Group B in terms of demographical information including gender, presence of diabetes, current smoking status, hyperlipidemia, whether a vein bypass or prosthetic bypass (polytetrafluethylene \[PTFE\] or Dacron® \[Invista, Wichita, KS\]) was performed, presence of femoral incision, and if the procedure was performed in a redo operative field (Table [2](#TAB2){ref-type="table"}).

###### Demographics of patients

\*Bovine carotid or cadaveric graft.

  ----------------------- --------------------- --------------------- --------------------- ---------
                          All                   Group A               Group B               p value
  Total (N)               215                   102                   113                    
  Gender                                                                                    0.340
  Female                  56 (26.0%)            23 (22.5%)            33 (29.2%)             
  Male                    159 (74.0%)           79 (77.5%)            80 (70.8%)             
  BMI                     27.8 \[24.6; 31.4\]   28.2 \[25.1; 31.5\]   27.6 \[24.2; 31.2\]   0.263
  Diabetes mellitus                                                                         0.763
  No                      134 (62.3%)           62 (60.8%)            72 (63.7%)             
  Yes                     81 (37.7%)            40 (39.2%)            41 (36.3%)             
  Current smoker                                                                            0.730
  No                      108 (50.2%)           53 (52.0%)            55 (48.7%)             
  Yes                     107 (49.8%)           49 (48.0%)            58 (51.3%)             
  Hyperlipidemia                                                                            0.201
  No                      15 (6.98%)            10 (9.80%)            5 (4.42%)              
  Yes                     200 (93.0%)           92 (90.2%)            108 (95.6%)            
  Vein graft                                                                                0.177
  No                      121 (56.3%)           52 (51.0%)            69 (61.1%)             
  Yes                     94 (43.7%)            50 (49.0%)            44 (38.9%)             
  Prosthetic                                                                                0.110
  No                      101 (47.2%)           54 (53.5%)            47 (41.6%)             
  Yes                     113 (52.8%)           47 (46.5%)            66 (58.4%)             
  Other\*                                                                                   0.482
  No                      207 (96.3%)           97 (95.1%)            110 (97.3%)            
  Yes                     8 (3.72%)             5 (4.90%)             3 (2.65%)              
  Non-femoral procedure                                                                     0.57
  No                      199 (92.6%)           96 (94.1%)            103 (91.2%)            
  Yes                     16 (7.4%)             6 (5.9%)              10 (8.8%)              
  Redo procedure                                                                            0.238
  No                      153 (71.2%)           77 (75.5%)            76 (67.3%)             
  Yes                     62 (28.8%)            25 (24.5%)            37 (32.7)              
  ----------------------- --------------------- --------------------- --------------------- ---------

The overall SSI rate for Group A was 11.8% (12/102). Group B had an overall SSI rate of 3.5% (4/113). Deep infection rate for Group A was 7% (7/102) and that for Group B was 1% (1/113) (Table [3](#TAB3){ref-type="table"}).

###### Deep and overall infection rates

  ------------------- ------------------ ------------------ -------------------- -------------------- ------------ ----------
                      Group A - actual   Group B - actual   Group A - expected   Group B - expected   Chi-square   p value
  Deep Infection      7                  1                  3.7                  4.3                  12.07        0.016867
  Overall infection   12                 4                  7.59                 8.41                 11.47        0.021758
  Total patients      102                113                                                                        
  ------------------- ------------------ ------------------ -------------------- -------------------- ------------ ----------

Cost analysis demonstrated a minimum of \$62,000 in infection-related cost savings between Group A and Group B even when accounting for the total cost of negative pressure wound therapy application (Table [4](#TAB4){ref-type="table"}).

###### Cost analysis for Groups A and B

SSI, surgical site infection; VAC, vacuum-assisted closure.

Deep SSI encountered in Group B is the actual hospital cost for patient.

Approximate cost superficial SSI = \$5,000.

Approximate cost deep SSI = \$20,000.

Approximate cost graft infection = N/A.

Approximate cost of Prevena = \$495.

  --------------------------- ----------- -------------------
                              Group A     Group B
  Cost superficial SSI        \$25,000    \$15,000
  Cost deep SSI               \$140,000   \$32,000 (actual)
  Cost graft infection        \$0         \$0
  Total infection cost        \$165,000   \$47,000
  Total cost incisional VAC   \$0         \$55,935
  Total cost                  \$165,000   \$103,000
  --------------------------- ----------- -------------------

Discussion
==========

SSIs are a significant burden for patients as well as have an impact on the healthcare expenditure \[[@REF2]\]. Superficial infections may only require outpatient treatment; however, some patients present to the Emergency Department and require IV antibiotics. Deep infections typically require IV antibiotics as well as surgical incision and drainage. Graft infections require an extensive hospital stay with graft explanation, IV antibiotics, and in most cases re-vascularization.

There are limitations to our study. First and foremost, this is a retrospective, single-center study. There have been randomized controlled trials demonstrating that negative pressure wound therapy decreases SSIs in vascular patients \[[@REF6]-[@REF8]\]. However, no randomized controlled trials have investigated routine use and cost savings in peripheral bypass patients. Secondly, our study was unable to account for malfunctioning Prevena devices or the length of time that they were maintained. Because bypass patients are typically discharged from the hospital within seven days, we have no way of telling if all patients complied with maintaining their dressing for a full seven days. In addition, pre-operative bundles were instituted during the time period of Group B. In January 2019, a SSI bundle was initiated at our institution. This included chlorohexidine bath and nasal swabs pre-operatively. Peri-operative antibiotic dosing was also tracked much more closely during the time period of Group B. The initiation of surgical bundles has been associated with reduced infection rates, although the literature has shown that ciNPT can decrease infection rates independently of SSI prevention bundles \[[@REF4],[@REF9]\]. This is a cofounding variable but perhaps ciNPT should be included in surgical bundles if reduced infections and cost savings are the result.

It is difficult to estimate costs associated with infections. Utilizing internal data for cost analysis is not ideal but offers the greatest insight for a hospital system. The cost of SSIs varies widely from institution to institution. Our cost of deep infections at \$20,000 is a very low estimation. Cost savings between the two groups was likely much more significant than our cost analysis conveys. Deep infections often require multiple surgical debridements as well as an extended hospital stay. Moreover, vascular surgery patients typically have multiple co-morbid conditions that contribute to the observed infection rate of 10%-20% in re-vascularization procedures \[[@REF1]\]. In fact, the American Society of Anesthesiologists (ASA) categorizes re-vascularization as a \"high risk\" procedure. The selective use of ciNPT may save our institution money if it is withheld in healthy patients. However, these patients are rare in the vascular world. If ciNPT were to prevent two deep infections per hundred bypasses, the device will pay for itself and prevent patient morbidity.

Conclusions
===========

Routine use of ciNPT is cost preventative and decreases both deep and superficial SSIs in vascular bypass patients. Our group has transitioned to the routine use of Prevena incisional therapy in all bypass patients as it has proven to be a cost-effective measure.
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